Primary brain tumours in adults (Q83911864)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

title

Primary brain tumours in adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Damien Ricard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

François Ducray

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

Marion Lahutte

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

Khê Hoang-Xuan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

Jean-Yves Delattre

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

16 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

volume

379

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

issue

9830

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1984-1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

Primary brain tumours in adults.

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Advanced MRI of adult brain tumors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Quantitative imaging biomarkers in neuro-oncology

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Genome-wide association study identifies five susceptibility loci for glioma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Molecular epidemiology of primary brain tumors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Cancer stem cells in nervous system tumors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Non-stem cell origin for oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Glioma stem cells: a midterm exam.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Two types of chromosome 1p losses with opposite significance in gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

IDH1 and IDH2 mutations in gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Genetic pathways to primary and secondary glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Angiogenesis in brain tumours

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Psychosocial and supportive-care needs in high-grade glioma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Radiotherapy for glioblastoma in the elderly.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Brain cancer propagating cells: biology, genetics and targeted therapies

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Compressing drug development timelines in oncology using phase '0' trials.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

A comprehensive outlook on intracerebral therapy of malignant gliomas.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Continuous growth of mean tumor diameter in a subset of grade II gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Seizure characteristics and control following resection in 332 patients with low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Preferential brain locations of low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Dynamic history of low-grade gliomas before and after temozolomide treatment

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Decreasing incidence rates of primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Primary lymphoma of the central nervous system: just DLBCL or not?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Analysis of perfusion weighted image of CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

The utility of body FDG PET in staging primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Combined modality therapy for primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Primary CNS lymphoma in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Long-term survival in primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

High-dose methotrexate for elderly patients with primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Delayed neurotoxicity in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)61346-9

7 January 2021

10.1016/S0140-6736(11)61346-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22510398 AND SRC:MED&resulttype=core&format=json

29 January 2020

1 reference